ADAP vs. ANL, KPTI, IZTC, CUE, HOWL, DRRX, ICCC, PDSB, DTIL, and ATNM
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Adlai Nortye (ANL), Karyopharm Therapeutics (KPTI), Invizyne Technologies (IZTC), Cue Biopharma (CUE), Werewolf Therapeutics (HOWL), DURECT (DRRX), ImmuCell (ICCC), PDS Biotechnology (PDSB), Precision BioSciences (DTIL), and Actinium Pharmaceuticals (ATNM). These companies are all part of the "pharmaceutical products" industry.
Adaptimmune Therapeutics vs. Its Competitors
Adaptimmune Therapeutics (NASDAQ:ADAP) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.
Adaptimmune Therapeutics has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -0.95, suggesting that its share price is 195% less volatile than the S&P 500.
Adaptimmune Therapeutics currently has a consensus price target of $1.35, indicating a potential upside of 2,647.29%. Adlai Nortye has a consensus price target of $9.00, indicating a potential upside of 426.01%. Given Adaptimmune Therapeutics' higher possible upside, equities analysts plainly believe Adaptimmune Therapeutics is more favorable than Adlai Nortye.
31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Adlai Nortye has lower revenue, but higher earnings than Adaptimmune Therapeutics.
Adlai Nortye has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -260.82%. Adlai Nortye's return on equity of 0.00% beat Adaptimmune Therapeutics' return on equity.
In the previous week, Adaptimmune Therapeutics and Adaptimmune Therapeutics both had 2 articles in the media. Adlai Nortye's average media sentiment score of 0.64 beat Adaptimmune Therapeutics' score of -1.00 indicating that Adlai Nortye is being referred to more favorably in the news media.
Summary
Adlai Nortye beats Adaptimmune Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ADAP) was last updated on 9/9/2025 by MarketBeat.com Staff
